Amarin Corp Plc (AMRN)

[HinduKush]

AN ENORMOUSLY IMPORTANT (PATENT 10881632) was released on Jan 5 2021 -->IMHO THIS IS perhaps as seminal a patent as the original chemical composition or R-IT effect patents already in place.
IT CATEGORICALLY LINKS THREE KEY CONCEPTS UNIQUE TO VASCEPA: (1) PROPRIETARY ENCAPSULATION GEL AND BLISTER PACK TECHNOLOGY (2) DISSOLUTION CHARACTERISTICS AND CONSEQUENT PLASMA LEVELS (AS COMPARED WITH CONVENTIONAL PREVALENT TYPE 2A GEL TECHNOLOGY) AND (3) THE THERAPEUTIC EFFECTS OF VASCEPA AS ESTABLISHED BY MARINE ANCHOR AND REDUCE-IT IN SPECIFIC CARDIOVASCULAR DISEASE POPULATIONS
It does not state a specific therapeutic level to be achieved but clearly shows that without this gel encapsulation a critical therapeutic level could NOT be achieved over a 24 hr let alone a 48 hour period. Since the unique therapeutic effects of VASCEPA are increasingly been tied to the PLASMA LEVELS of EPA achieved (and not to any specific lipid or other biomarker effects, it becomes CRITICALLY important to establish a nexus between the method of achieving this critical plasma level on a CONSISTENT SUSTAINED basis (the encapsulation technology) AND the resultant benefit (lipid therapeutic or otherwise (eg COVID). Encapsulation is no longer just a means to prevent degradation --It is a means to achieve a CRITICAL plasma level and hence obtain a critical therapeutic effect. Incidentally, it establishes a critical level of degradation consistent with these therapeutic benefits ie peroxidation levels of between 5-20 meq/mg, specifically demonstrated to be achieved by this proprietary encapsulation technology.
I am sure as the evidence for sustained elevated plasma levels of EPA >100 ug/ml becomes obvious after the failure of STRENGTH and OMEMI, this finding will assume great patent and clinical relevance. Methods and details matter.
I have depicted all the relevant findings in a pictographic format so it is easier to understand: